155 related articles for article (PubMed ID: 12954577)
1. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
Baselga J; Llombart-Cussac A; Bellet M; Guillem-Porta V; Enas N; Krejcy K; Carrasco E; Kayitalire L; Kuta M; Lluch A; Vodvarka P; Kerbrat P; Namer M; Petruzelka L
Ann Oncol; 2003 Sep; 14(9):1383-90. PubMed ID: 12954577
[TBL] [Abstract][Full Text] [Related]
2. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
Buzdar A; O'Shaughnessy JA; Booser DJ; Pippen JE; Jones SE; Munster PN; Peterson P; Melemed AS; Winer E; Hudis C
J Clin Oncol; 2003 Mar; 21(6):1007-14. PubMed ID: 12637464
[TBL] [Abstract][Full Text] [Related]
3. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
Downs RW; Moffett AM; Ghosh A; Cox DA; Dowsett SA; Harper K
Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
[TBL] [Abstract][Full Text] [Related]
4. Arzoxifene as therapy for endometrial cancer.
Burke TW; Walker CL
Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S40-6. PubMed ID: 12928005
[TBL] [Abstract][Full Text] [Related]
5. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.
Deshmane V; Krishnamurthy S; Melemed AS; Peterson P; Buzdar AU
J Clin Oncol; 2007 Nov; 25(31):4967-73. PubMed ID: 17971595
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.
McMeekin DS; Gordon A; Fowler J; Melemed A; Buller R; Burke T; Bloss J; Sabbatini P
Gynecol Oncol; 2003 Jul; 90(1):64-9. PubMed ID: 12821343
[TBL] [Abstract][Full Text] [Related]
7. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy.
Wu L; Tannock IF
Clin Cancer Res; 2005 Nov; 11(22):8195-200. PubMed ID: 16299252
[TBL] [Abstract][Full Text] [Related]
8. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
Goldstein SR; Bhattoa HP; Neven P; Cox DA; Dowsett SA; Alam J; Sipos A; Muram D
Menopause; 2012 Jan; 19(1):41-7. PubMed ID: 21993078
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Münster PN; Buzdar A; Dhingra K; Enas N; Ni L; Major M; Melemed A; Seidman A; Booser D; Theriault R; Norton L; Hudis C
J Clin Oncol; 2001 Apr; 19(7):2002-9. PubMed ID: 11283133
[TBL] [Abstract][Full Text] [Related]
10. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.
Bolognese M; Krege JH; Utian WH; Feldman R; Broy S; Meats DL; Alam J; Lakshmanan M; Omizo M
J Clin Endocrinol Metab; 2009 Jul; 94(7):2284-9. PubMed ID: 19351734
[TBL] [Abstract][Full Text] [Related]
11. Arzoxifene in breast cancer.
Chan S
Eur J Cancer; 2002 Nov; 38 Suppl 6():S55-6. PubMed ID: 12409075
[No Abstract] [Full Text] [Related]
12. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
Fabian CJ; Kimler BF; Anderson J; Tawfik OW; Mayo MS; Burak WE; O'Shaughnessy JA; Albain KS; Hyams DM; Budd GT; Ganz PA; Sauter ER; Beenken SW; Grizzle WE; Fruehauf JP; Arneson DW; Bacus JW; Lagios MD; Johnson KA; Browne D
Clin Cancer Res; 2004 Aug; 10(16):5403-17. PubMed ID: 15328178
[TBL] [Abstract][Full Text] [Related]
13. Arzoxifene: the development and clinical outcome of an ideal SERM.
Munster PN
Expert Opin Investig Drugs; 2006 Mar; 15(3):317-26. PubMed ID: 16503767
[TBL] [Abstract][Full Text] [Related]
14. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
15. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
Chan S
Semin Oncol; 2002 Jun; 29(3 Suppl 11):129-33. PubMed ID: 12138407
[TBL] [Abstract][Full Text] [Related]
16. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
Powles TJ; Diem SJ; Fabian CJ; Neven P; Wickerham DL; Cox DA; Muram D; Agnusdei D; Dowsett SA; Amewou-Atisso M; Cummings SR
Breast Cancer Res Treat; 2012 Jul; 134(1):299-306. PubMed ID: 22484799
[TBL] [Abstract][Full Text] [Related]
18. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Cummings SR; McClung M; Reginster JY; Cox D; Mitlak B; Stock J; Amewou-Atisso M; Powles T; Miller P; Zanchetta J; Christiansen C
J Bone Miner Res; 2011 Feb; 26(2):397-404. PubMed ID: 20658564
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Mocellin S; Pilati P; Briarava M; Nitti D
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582062
[TBL] [Abstract][Full Text] [Related]
20. Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Palkowitz A; Jee WS; Turner CH; Sato M
J Bone Miner Res; 2002 Dec; 17(12):2256-64. PubMed ID: 12469920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
